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Abstract 
Cancer is one of the leading causes of death in Japan and the U.S. In 
spite of new cancer treatments having been recently developed, such as 
molecular targeted and immuno-oncology therapies, to augment traditional 
treatments like irradiation and chemotherapeutic agents, there remains a high 
level of unmet medical needs in the area of cancer therapy. Cancer cells utilise 
various biological mechanisms to escape the stress of treatment and such 
inherent or acquired resistance makes cancer treatment more difficult. 
Therefore, a treatment strategy to overcome cancer resistance is required.  
In this study, I focused on two cancer-related genes, aurora B kinase 
and malic enzyme 1, which have different biological functions and elucidated 
the resistance mechanism of cancer cells when the functions of these genes 
was inhibited. Applying the concept of synthetic lethality, I demonstrated that 
simultaneous inhibition of the resistance mechanism of both cancer-related 
genes synergistically suppressed cancer cell growth. 
In Chapter I, I will describe my research on aurora B kinase inhibition. 
By siRNA screening, Bcl-xL was found as a key protein of resistance 
mechanism of cancer cells against aurora kinase B inhibition through 
inactivation of BAX. At the same time, the combination of the aurora B kinase 
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inhibitor with the Bcl-xL inhibitor synergistically inhibited cancer cell 
proliferation with apoptosis induction. 
In Chapter II, I will describe my research on malic enzyme 1 inhibition. 
It was determined that malic enzyme 1 and the glycolysis pathway function 
complementary to one another to produce NADPH and to sustain redox 
homeostasis in cancer cells and work as a resistance mechanism. In addition, 
simultaneous inhibition of malic enzyme 1 and glycolysis synergistically 
suppressed cancer cell growth. 
In conclusion, I suggest that cancer cells have various resistance 
mechanisms against stress; however, these resistance mechanisms could be a 
vulnerability of cancer cells and a target of combination treatment. Such a 
treatment strategy could help overcome cancer resistance, thereby addressing 
the unmet medical needs of cancer patients. 
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Abbreviations 
 
BAK  BCL2 antagonist/killer 1 
BAX  BCL2 associated X, apoptosis regulator 
BBC3 BCL2 binding component 3 
BCL-xL B-cell lymphoma-extra large 
BCL2L1 BCL2 like 1 
BRCA1/2 Breast cancer susceptibility gene 1/2 
CDKN1A Cyclin-dependent kinase inhibitor 1A 
DAPI  4, 6-diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
EGFR Epidermal growth factor receptor 
FACS Fluorescence-activated cell sorting 
FSC  Forward scatter 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
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G6PD Glucose-6-phosphate dehydrogenase 
HMOX-1 Heme oxygenase 1, HO-1 
IDH  Isocitrate dehydrogenase 
MCL1 Myeloid cell leukemia sequence 1 
ME  Malic enzyme 
NADPH Nicotinamide adenine dinucleotide phosphate 
NSCLC Non-small cell lung cancer 
PBS  Phosphate-buffered saline 
PI  Propidium iodide 
PIDD1 p53-induced death domain protein 1 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) 
PPP  Pentose phosphate pathway 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
R5P  Ribose-5-phosphate 
SDS  Sodium dodecyl sulfate 
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siRNA Small interfering RNA 
TCA  Tricarboxylic acid 
TKI  Tyrosine kinase inhibitor 
TP53  Tumour protein 53 
5-FU  5-fluorouracil 
6PDG 6-phosphogluconate dehydrogenase 
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General Introduction 
 
High unmet medical needs of cancer treatment 
Since 1981, cancer has been the leading cause of death in Japan; two in  
seven Japanese individuals died from cancer in 2015, although the five-year 
survival rate has gradually improved in Japan (62.1 %) and the U.S (68 %) 
according to cancer statistics report (1, 2). For a long time, three therapeutic 
strategies, namely chemotherapy, surgery, and irradiation therapy, have been 
the primary forms of cancer therapy. Recently, since molecular targeted 
therapy and emerging new therapy like immune checkpoint inhibitors (3, 4), 
which focuses on immuno-oncology, are showing survival rates of cancer 
patients being much improved in these years. However, the number of cancer 
patients who receive the benefit of the new therapies is still limited and there 
are still a lot of unmet medical needs. Therefore, we need to continue our 
struggle to cure all of cancers by developing new therapies and treatment 
strategies. 
Inherent/ acquired resistance to treatment in cancer 
What makes cancer treatment so difficult? One of the answers to this 
question is that cancer inherently has, or develops, resistance mechanisms 
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against the stress induced by the treatment, thus increasing the recurrent rate 
of cancer. There are many known factors which make cancer cells resistant to 
treatment and increase the recurrence rate of cancer (5).  
First, the pharmacokinetics of drug substance is important to exert 
potency of drug in cancer cells. Pharmacokinetics is described by the 
absorption, distribution, metabolism, and elimination of a drug substance in 
the body. Drug substances are delivered to tumours through the blood and get 
incorporated into cancer cells and they then affect cancer cell viability. Some 
of the cancer cells express drug efflux pumps, such as p-gp, which is an ABC 
transporter, and acquire drug resistance by increasing the efflux of the drug 
substance. Some drugs are activated by being metabolized by metabolic 
enzymes in cancer cells. For example, Capecitabine, which is a prodrug of 5-
FU, exercises its potency by  thymidine phosphorylase  in cancer cells (6). It is 
known that the gene encoding thymidine phosphorylase is inactivated by DNA 
methylation  in a certain cancer cells and those cells are resistant to 
Capecitabine treatment (7). Thus, cancer cells could be resistant to drugs by 
lowering drug concentration in cells.  
11 
 
Second, a tumour consists of multiple cancer cells, and every cell has 
various gene mutations and different characteristics, which is called tumour 
heterogeneity. When a tumour is treated with a drug, some sub-populations of 
cancer cells are suppressed while other sub-populations cannot be affected by 
the drug and become recurrent tumours (8). Variations in the 
microenvironment of tumours is also a factor, depending on blood vessel 
formation, nutrient/ oxygen concentration, immune cell infiltration and 
stromal cell types etc. (9, 10) which could change the response to treatment. 
Third, although there are multiple cancer types depending on which 
organ the cancer cell is derived from or which primary and metastatic site the 
cancer cells locates, preferable drugs for each type of cancer are not developed 
and not appropriately selected in clinic (11).  
Finally, even if a tumour is reduced by treatment with a highly potent 
drug, a certain sub-population of cancer cells in that tumour acquire resistance 
against the drug through various biological mechanisms, and the tumour 
grows again (5). Cancer cells acquires drug resistance mainly by three 
mechanisms: alternation of the target, adaptive responses, and dysfunction of 
apoptosis (5).  It is well known that cancer cells tend to acquire drug 
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resistance by gene mutations when they are treated with a molecular therapy 
targeting a driver gene. The epidermal growth factor receptor (EGFR), a 
putative driver oncogene, is over expressed in many cancers, including non-
small cell lung cancer (NSCLC). The first-generation of EGFR tyrosine kinase 
inhibitors (TKIs), such as gefitinib and erlotinib, were effective as a first-line 
treatment of EGFR mutant NSCLC, however, the EGFR T790M resistance 
mutation emerged in most of patients. In EGFR T790M mutant cells, first-
generation TKIs cannot inhibit the activity of EGFR. For the treatment of 
EGFR mutant resistant tumours, the second-generation EGFR-TKI, Afatinib, 
has been used. Currently, the third-generation EGFR-TKI, Osimertinib, is 
used for afatinib-resistant NSCLCs that have an additional EGFR mutation. 
Thus, cancer cells acquire drug resistance by harbouring mutations that alter 
the potency of a drug on a target. In addition, cancer cells become resistant to 
treatment by adaptive response, in which cancer cells activate redundant 
pathways in stressful treatment conditions. Vemrafenib, which is BRAF 
inhibitor, is used for BRAF-V600E mutant melanoma in clinics, however, 
most patients develop resistant tumours (12). One of the resistance 
mechanisms is the activation of the EGFR and AKT signalling axis, which is a 
redundant growth signal in cancer cells (13). Cancer cells flexibly activate 
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intra-cellular bypass pathways to overcome various temporal stress caused by 
a treatment and grow again. Regulation of balance of the survival and 
apoptosis signals are required to maintain the homeostasis in cells. Therefore, 
the dysfunction of apoptosis causes aberrant growth of cells and results in 
cancer development. It could also make cancer cells resistant to drugs.  
Pre-clinical translational research to overcome drug resistance 
In order to overcome these issues, translational research is the focus of 
current drug discovery studies. Translational research, also called translational 
medicine, is defined as “an interdisciplinary branch of the biomedical field 
supported by three main pillars: beachside, bedside and community. The goal 
of translational medicine is to combine disciplines, resources, expertise, and 
techniques within these pillars to promote enhancements in prevention, 
diagnosis, and therapies.” by the EUSTM (14, 15). Based on this concept, 
basic research relating to MoA-driven target cancer selection, patient 
stratification markers, and effective combination therapy is required to 
improve the probability of drug discovery in the clinic. This concept is also 
applied for development of therapies to overcome resistant and recurrent 
tumours against first therapy.  
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Cancer vulnerability and treatment 
Recently, the concept of synthetic lethality is coming under the 
spotlight in cancer treatment (16). Synthetic lethality is when a combination of 
deficiencies in the expression of two genes leads to cell death, but a deficiency 
in only one of the genes does not. The best known drug that makes use of this 
concept for cancer treatment is the PARP (poly(ADP-ribose) polymerase) 
inhibitor (17). PARP is an enzyme that is involved in DNA single-strand 
break repair, and inhibition of PARP induces DNA double-strand breaks. In 
normal cells, DNA double-strand break is repaired by homologous 
recombination, so normal cells are not affected by PARP inhibition. It is well 
known that PARP inhibitor shows selective tumour suppressive effects on 
BRCA1/2 mutant cells. BRCA1 and BRCA2 are key components of the 
homologous recombination machinery and its mutation results in the 
dysfunction of the DNA double-strand break repair mechanism. Therefore, in 
BRCA1/2 mutant cancer cells, cells cannot repair DNA damage of double 
strand break caused by PARP inhibition and are killed. That is, BRCA1/2 
mutant cells have vulnerability to PARP inhibition and synthetic lethality. 
Thus, applying the concept of synthetic lethality is a prospective approach to 
treat cancer by targeting the vulnerability of cancer 
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Objectives in this research 
In this study, I focused on two cancer-related genes, aurora B kinase 
(Chapter I) and malic enzyme 1 (Chapter II), which have different biological 
functions in cancer cells, and I determined that cancer cells activates a certain 
resistance mechanism against the inhibition of cancer-related genes. In 
addition, I demonstrated that the acquired resistance of cancer cells itself 
could be a vulnerability of cancer cells and would be a therapeutic target to 
overcome resistance mechanisms of cancer cells.  
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Chapter I 
 
Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing 
Active BAX in Cancer Cells 
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Abstract 
 
Aurora B kinase plays an essential role in chromosome segregation and 
cytokinesis, and is dysregulated in many cancer types, making it an attractive 
therapeutic target. TAK-901 is a potent aurora B inhibitor that showed 
efficacy in both in vitro and in vivo oncology models. In this study, I 
conducted a synthetic lethal siRNA screening to identify the genes that, when 
silenced, can potentiate the cell growth-inhibitory effect of TAK-901.  
It was found that B-cell lymphoma-extra large (BCL-xL) depletion by 
siRNA or chemical inhibition synergized with TAK-901 in cancer cell lines. 
As a mechanism of synthetic lethality, active BCL2 associated X, apoptosis 
regulator (BAX) was induced by TAK-901. BCL-xL protected cells from 
BAX-dependent apoptosis induction. Therefore, TAK-901 sensitizes cancer 
cells to BCL-xL inhibition.  
My data demonstrate that polyploid cells induced by TAK-901 are 
vulnerable to BCL-xL inhibition. My findings may have an impact on 
combination strategies with aurora B inhibitors in clinical studies. 
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Introduction 
 
Aurora B is a component of the chromosomal passenger complex that is 
essential for chromosome condensation, spindle assembly checkpoint , and 
cytokinesis (18, 19). Aurora B is highly expressed in various human cancer 
types (20) and is associated with poor prognosis and progression (21, 22), 
making it an attractive therapeutic target. Farrell et al. previously identified a 
potent aurora B inhibitor, TAK-901, for the treatment of cancer with aurora B 
dysregulation (23). It is reported that aurora B inhibition with a small 
molecule inhibitor, such as TAK-901, leads to abnormal chromosome 
alignment and silencing of the spindle assembly checkpoint. This induces the 
cells to exit mitosis without completion of cytokinesis, resulting in a polyploid 
cellular phenotype (23–25). Although aurora B kinase inhibitors induce cell 
growth inhibition both in vitro and in vivo, some polyploid cells remain after 
the treatment. Multiple aurora B inhibitors have been tested in clinical trials as 
a monotherapy with limited success (26); a combination strategy targeting the 
vulnerability of polyploid cancer cells to aurora B kinase inhibitors may 
potentiate their therapeutic effects. 
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The concept of synthetic lethality emerged over a dozen years ago. 
Targeting of a gene that is synthetically lethal to a cancer-related mutation 
would specifically suppress cancer cells (27). This strategy enables treatment 
of cancer with a wide therapeutic index. The concept of synthetic lethality is 
not only used in mutation-related cancer, but is also applied to explore 
combination partners , and to identify vulnerability of cancer cells in specific 
microenvironments in accordance with the increased availability of chemical 
and genetic tools to interfere with gene function (28–30). 
In this study, I conducted a siRNA screen of druggable genes to identify 
genes indispensable for the survival of polyploid cells, investigated the 
mechanism of vulnerability of polyploid cells induced by TAK-901, and 
applied the findings to a combination strategy with TAK-901. 
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Materials and Methods 
 
Cell lines and culture.   
Human cancer cell lines, SW480, HCT116, SW620, HT29, U87, A549, 
H23, H28, H1299, LNCap, H146, H196, H1395, H446, H1688, H209, H510A, 
and H1048 were purchased from the American Type Culture Collection 
(Manassas, VA, USA). All cell lines were cultured according to the supplier’s 
recommendations. 
 
Small molecules and siRNAs.  
TAK-901 was obtained from Takeda California, Inc. (San Diego, CA, 
USA). ABT-263 (31) was purchased from Funakoshi (Tokyo, Japan), and 
AZD1152-HQPA (32) and gossypol were obtained from Sigma-Aldrich (St. 
Louis, MO, USA). For the siRNA screening, the Human Druggable Genome 
siRNA Set Ver. 4.1 was purchased from QIAGEN (Hilden, Germany). 
SilencerSelect Negative Control No. 2 and BCL2 like 1 (BCL2L1) (s1921, 
s1922), BAX (s1889, s1890), BCL2 antagonist/killer 1 (BAK) (s1880, s1881), 
and tumour protein 53, (TP53) (s605, s606) SilencerSelect siRNAs were 
purchased from Thermo Fisher scientific (Waltham, MA, USA). 
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siRNA transfection.  
The siRNA screening was conducted by solid-phase transfection in a 
1536-well plate format (33). Shortly, HCT116 cells were seeded at 150 
cells/well in 1536-well plates and dimethyl sulfoxide (DMSO) or 100 nM 
TAK-901 were added to the wells 24 hours after cell seeding. After 72 hours 
of incubation, cell proliferation was measured using CellTiter Glo. For 
individual siRNA experiments, HCT116 cells were seeded at 2,000 cells/well 
in 96-well plates and simultaneously transfected with siRNAs using 
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s recommendations. 
Individual siRNAs were transfected at a final concentration of 10 nM. For 
simultaneous treatment with siRNA and compounds, cells were transfected 
with indicated siRNAs for 24 hours followed by a 72-hour incubation with 
each compound at given concentrations. 
 
Cell proliferation assay Caspase-3/7 assays.  
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For general cell proliferation assay, 5000 cells were seeded in 96 well 
plates and cultured for 24 hours. Then, cells were treated with TAK-901, 
AZD1152-HQPA or ABT-263 for 72 hours. Cell viability was determined 
using the CellTiter-Glo luminescence assay (Promega, Madison, WI, USA) 
according to manufacturer’s protocol. Luminescent signals were detected 
using an ARVO MX1420 microplate reader (PerkinElmer, Wellesley, MA, 
USA). Caspase-3/7 activity was determined using the Caspase-Glo 3/7 Assay 
(Promega, Fitchburg, WI, USA) per the manufacturer’s protocol. 
 
Analysis of combination effect.  
The Delta Plot Analysis method was used to determine whether the 
effect of a drug combination treatment was synergistic or additive. The Delta 
Plot Analysis method uses either a Bliss Independence or Loewe Additivity 
model. The method is comparative in nature, and results are plotted as a 
function of cell survival, with confidence intervals for determining 
significance above/below an additive effect line (34). 
 
23 
 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR ) 
analysis.  
Following the designated treatment, total RNA was isolated from cells 
and purified with an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer’s instructions. qPCR analysis was performed on 
a ViiA7 (Applied Biosystems, Foster City, CA, USA), using TaqMan Fast 
Advanced Master Mix with TaqMan probes. Data were analyzed according to 
the 2–ΔΔCt method and normalized to the amount of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA. The normalized abundances of 
target mRNAs were expressed relative to the corresponding values for cells 
treated with DMSO or negative control siRNAs. The following TaqMan 
probes were used for quantitative RT-PCR analysis: GAPDH 
(Hs02786624_g1), BAX (Hs00180269_m1), BCL2L1 (Hs99999146_m1), 
TP53 (Hs01034249_m1), cyclin dependent kinase inhibitor 1A (CDKN1A) 
(Hs00355782_m1), phorbol-12-myristate-13-acetate-induced protein 1 
(PMAIP1, NOXA) (Hs00560402_m1), BCL2 binding component 3 (BBC3) 
(Hs00248075_m1), p53-induced death domain protein 1 (PIDD1) 
(Hs00611142_g1) (Applied Biosystems, Waltham, MA, USA). 
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Western blotting.  
Whole cell extracts were prepared with 1x Laemmli sample buffer 
(Tris-HCl 125 mM pH 7.5, 1% sodium dodecyl sulfate (SDS), 20% glycerol). 
Whole cell extracts or immunoprecipitates were fractionated by SDS-poly-
acrylamide gel electrophoresis, and transferred to polyvinylidene difluoride 
membranes using an iBlot Transfer Stack and iBlot Gel Transfer Device 
(Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA). After incubation 
with StartingBlock™ T20 in phosphate-buffered saline (PBS) Blocking Buffer 
(Pierce Biotechnology, Rockford, IL, USA), the membranes were incubated 
overnight with primary antibodies, followed by a 1-hour incubation with 
horseradish peroxidase-conjugated secondary antibodies (Cell Signaling 
Technology, Beverly, MA, USA). For imaging, the membranes were soaked 
in ImmunoStar Zeta (Wako, Osaka, Japan) and scanned using an ImageQuant 
LAS-3000 (Fujifilm, Tokyo, Japan). Mitochondrial fractionation was 
conducted using Qproteome Mitochondria Isolation Kit (Qiagen). The 
following antibodies were used for immunoprecipitation or western blot 
analysis: anti-p53 (DO-1, sc-126) and anti-p21 (C-19, sd-397) from Santa 
Cruz Biotech (Dallas, TX, USA), anti-BAX (#2772), anti-BAK (#3814), anti-
pHistoneH3 (#9715), anti-GAPDH (#2118), anti-BCL2L1 (53H6, #2764), and 
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anti-MCL1 (#4572) from Cell Signaling Technologies (Danvers, MA, USA), 
anti-BAX (6A7, ab5714) from Abcam (Cambridge, UK). 
 
Immunoprecipitation.  
In general, cells were lysed in RIPA buffer on ice. For 
immunoprecipitation with BAX 6A7 antibodies (Abcam, Cambridge, UK), 
cells were lysed in 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate on ice. For immunoprecipitation, cell lysate was incubated 
with Dynabeads Protein G ( Invitrogen) conjugated with BAX, BCL-xL, or 
MCL1 antibodies overnight at 4°C with gentle rocking. Following three 
washes with lysis buffer, the bound proteins were eluted from the beads with 
2× Laemmli sample buffer. The immunoprecipitated samples were analyzed 
by western blotting. 
 
Fluorescence-activated cell sorting (FACS) analysis.  
HCT116 cells were pelleted, washed twice with PBS, and suspended in 
150 μL of cold PBS. Cold 100% ethanol (350 μL) was added to the cell 
suspensions, which were then vortexed and incubated at −20°C for 30 minutes. 
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The cells were pelleted, resuspended in PBS containing 32 ng/μL RNase A 
(Sigma-Aldrich), and incubated at room temperature for 30 minutes. 
Propidium Iodide (PI) was added at a concentration of 40 ng/μL, and the cells 
were incubated for 10 minutes at room temperature. Samples were analyzed 
by FACS for cell-cycle distribution. 
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Results 
 
Druggable siRNA screen reveals that BCL-xL knock-down synergizes 
with TAK-901.  
As reported previously, enlarged nuclei in HCT116 cells appeared after 
TAK-901 treatment (23), which demonstrated that TAK-901 induced 
polyploid cells. The phenotype is caused by aurora B inhibition, as confirmed 
by treatment with AZD1152-HQPA, a selective aurora B kinase inhibitor 
(Figure 1A). Induction of polyploidy was also detected by FACS analysis; 2N 
and 4N cells were observed in DMSO-treated HCT116 cells, while mainly 4N 
and 8N were observed in TAK-901- or AZD1152-HQPA-treated HCT116 
cells (Figure 1B). To identify genes that, when knocked down, synergize with 
TAK-901, I conducted a screen against a library of 27,921 siRNAs targeting 
6,870 druggable genes. The screen was conducted using the solid-phase 
reverse transfection method (35) on the HCT116 cell line in 1536-well plates 
(Figure 1C). The screen was performed twice, with high reproducibility 
(correlation factor=0.833) (Figure 1D). Hit genes were selected based on the 
criterion that more than two siRNA sequences satisfied a Z-score of -1.2 or 
less in two experiments (Figure 1E). In total, 13 genes fulfilled this criterion 
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(Figure 1F). I confirmed the screening results using siRNAs with different 
sequences from another vendor and found that BCL-xL knock-down 
synergized well with TAK-901 or AZD1152-HQPA in HCT116 cells (Figure 
1G and 1H). In agreement with these observations, a synergistic effect was 
observed when both aurora B and BCL-xL were knocked down (Figure 1I). 
These results suggest that genetic knock-down of BCL-xL synergizes with 
TAK-901 in HCT116 cells. 
Chemical BCL-xL inhibition synergizes with TAK-901 in cancer cell lines.  
To confirm the synergistic effect of TAK-901 with siRNA-mediated 
BCL-xL knock-down, I performed a combination treatment of TAK-901 or 
AZD1152-HQPA with ABT-263, a small-molecule BCL2/BCL-xL inhibitor. 
Synergistic cell growth inhibition of HCT116 cells was observed when TAK-
901 and ABT-263 were combined (Figure 2A). Caspase-3/7 activity was also 
enhanced 24 hours after the combination treatment as compared to each 
treatment alone, indicating that apoptosis was synergistically induced (Figure 
2B). Similar results were observed when using AZD1152-HQPA with ABT-
263 (Figure 2C and 2D). I conducted a larger combinatorial study with 18 
human cancer cell lines including colorectal cancer (CRC), non-small cell 
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lung cancer (NSCLC), small cell lung cancer (SCLC), and prostate cancer and 
glioblastoma cells using Delta Plot Analysis, a novel graphical approach (34), 
to calculate additive or synergistic interactions between TAK-901 and ABT-
263. I found that TAK-901 or AZD152-HQPA and ABT-263 synergistically 
inhibited cell growth in multiple cell lines, regardless of the cancer type 
(Figure 2E and 2F). The synergistic effect was also observed when gossypol, a 
different BCL-xL inhibitor, was combined with TAK-901 (Figure 2G). 
Overall, these results showed that combined inhibition of aurora B and BCL-
xL can result in synergistic cancer cell killing. 
TAK-901 increases active BAX at mitochondria p53-dependently and 
induces BAX-dependent apoptosis in combination with ABT-263.  
To elucidate the mechanism of the combination effect of TAK-901 and 
ABT-263, I examined the regulation of pro- and anti-apoptotic proteins in 
HCT116 cells. I found that the protein levels of BAX, p53, and p21, but not 
BAK, were increased by TAK-901 in HCT116 cells, whereas Ser10 
phosphorylation of histone H3, a substrate of aurora B kinase, was suppressed 
(Figure 3A). mRNA expression of BAX was also increased by TAK-901 
(Figure 3B). mRNA expression of p53 downstream proteins p21 and PIDD1, 
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but not NOXA and BBC3, was enhanced by TAK-901 treatment (Figure 3C). 
To confirm that BAX gene induction by TAK-901 was p53-dependent, I 
investigated BAX expression under the condition of p53 depletion by mRNA 
knock-down. In the absence of p53, expression of BAX, as well as p21, was 
reduced at the mRNA and protein levels (Figure 3D and E), indicating that 
TAK-901 induces BAX expression in a p53-dependent manner in HCT116 
cells. Cell growth inhibition by combination treatment of TAK-901 and ABT-
263 was relieved by p53 depletion (Figure 3F), suggesting that p53 plays a 
role in the combination effect. 
BAX is a key to the synergistic effect and is suppressed by BCL-xL.  
To investigate whether BAX induced by TAK-901 was activated, I 
immunoprecipitated cellular BAX protein with the BAX 6A7monoclonal 
antibody, which recognizes the active BAX protein conformation. TAK-901 
slightly increased active BAX monomer as well as total BAX protein in 
HCT116 cells. Immunoprecipitation of BCL-xL revealed that it was bound to 
BAX, but this binding was completely abrogated by ABT-263 in HCT116 
cells. MCL1 expression was also slightly reduced by TAK-901 treatment. In 
A549 cells, BAX expression was not increased by TAK-901, but an increase 
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in active BAX protein and reduced binding to BCL-xL and MCL1 were 
observed, which is consistent with the findings in HCT116 (Figure 4A). Low 
levels of BAK protein were found in HCT116 cells, and binding to BCL-xL 
was not detected (Figure 4B). After TAK-901 treatment, BAX was 
translocated from the cytoplasm to the mitochondrial membrane (Figure 4C). 
To confirm that BAX expression is critical for the synergy of TAK-901 and 
ABT-263, BAX expression was suppressed by siRNA in combination with 
inhibitor treatment. BAX knock-down cancelled the cell growth inhibition and 
apoptosis induced by TAK-901/ABT-263 or AZD1152-HQPA/ABT-263 
combination treatment of HCT116 cells (Figure 4D-4G). Furthermore, the 
synergy was not observed in the BAX null HCT116 cell line (Figure 4H and 
4J). Similar results were obtained in combination with AZD1152-HQPA and 
ABT-263 (Figure 4I and 4K). Therefore, BAX is a critical factor in mediating 
the synergistic effects of combined inhibition of aurora B kinase and BCL-xL. 
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Discussion 
 
TAK-901 is a potent aurora B inhibitor that causes cell-growth 
inhibition in multiple cancer cell lines and induces a multinucleated polyploid 
phenotype. I conducted a synthetic lethal siRNA screen to elucidate the 
vulnerability of polyploid HCT116 cells treated with TAK-901. My screen 
identified BCL-xL as a key molecule rendering cancer cells resistant to TAK-
901-induced cell killing. 
TAK-901 suppressed cellular phosphorylation of histone H3, which is a 
direct substrate of aurora B kinase, and induced polyploidy with p53 
activation in HCT116 cells. p53 is known to be a guardian that inhibits 
tumorigenesis by eliminating tetraploid or aneuploid cells, which are 
hallmarks of solid tumours (36). TAK-901 may make cancer cells more prone 
to undergo apoptosis by inducing polyploidy and subsequent p53 activation. 
My results showed that BAX is induced by TAK-901 in a p53-
dependent manner in HCT116 cells. Furthermore, the active form of BAX was 
increased and translocated to the mitochondrial membrane by TAK-901. BAX 
is known to be a pro-apoptotic protein and when activated, it localizes to the 
mitochondrial membrane where it forms oligomers which induce 
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mitochondrial outer membrane permeabilization and apoptosis (37). Therefore, 
TAK-901 renders HCT116 cells sensitive to apoptosis by increasing the 
expression of BAX through p53. 
To clarify the mechanism of apoptosis induced by the combination 
treatment, I silenced BAX or BAK expression in combination with TAK-901 
and ABT-263 treatment in HCT116 cells. Apoptosis induction and subsequent 
cell growth inhibition by the combination treatment were cancelled by BAX 
but not BAK depletion, indicating that BAX is indispensable for the 
combination effect. In HCT116 cells, I observed that BCL-xL is bound to 
BAX. BCL-xL is a pro-survival BCL2 family protein that binds to BAX and 
inhibits its pro-apoptotic activity at the mitochondrial outer membrane. 
Therefore, although TAK-901 induces BAX activation, BCL-xL binds to 
BAX and suppresses apoptosis induction. Once BAX is released from BCL-
xL by ABT-263 or BCL-xL depletion, apoptosis is evoked in cancer cells. 
That is, BCL-xL rescues cells from the cell growth inhibition induced by 
TAK-901 and therefore, cancer cells treated with TAK-901 are vulnerable to 
BCL-xL inhibition.  
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I observed synergism between TAK-901 and BCL-xL inhibition by 
both siRNAs and the inhibitors ABT-263 and gossypol in the HCT116 cell 
line. Synergistic cell-growth inhibition by Aurora B and BCL-xL knock-down 
and the selective aurora B inhibitor AZD1152 were also demonstrated. This 
result is consistent with a previous report by Shah et al. (38).  
The combination effect of TAK-901 and ABT-263 was observed in 
multiple cancer cell lines, but it was not synergistic in all. The synergistic 
effect was also observed in A549, a non-small cell lung cancer cell line that 
expresses wild-type p53. Although total BAX expression was not increased by 
TAK-901 in A549 cells, active BAX and binding of BAX to BCL-xL were 
increased by TAK-901, suggesting that BAX is not always activated by p53 in 
cancer cells. The presence or absence of all possible determinants of the 
synergistic effect in each cell line was not elucidated; however, I demonstrated 
that activation of BAX is a key to the combination effect. As BAX activity is 
regulated by several mechanisms at the mRNA and post-translational levels 
(37), BAX may be activated by TAK-901 in different ways depending on the 
cellular context. 
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In conclusion, I identified BCL-xL inhibition as vulnerability of 
polyploid cells induced by TAK-901 through a synthetic lethal siRNA screen. 
My findings elucidated that induction of active BAX is a key mechanism of 
the revealed combination effect. Treatment with TAK-901, or other aurora B 
inhibitors, and BCL-xL inhibitors such as ABT-263 represents a promising 
biologically relevant combination strategy to treat cancer in the clinic. My 
study demonstrates that siRNA screening is valuable in elucidating cellular 
vulnerability under compound-treated conditions and in identifying targets for 
a biologically relevant combination strategy for anticancer therapies. 
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Tables and Figures 
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Figure 1. TAK-901 synthetic lethality screen with druggable gene siRNA 
library reveals that BCL-xL knock-down synergizes with TAK-901.  
(A) HCT116 cells were treated with 100 nM TAK-901 or 100 nM AZD1152-
HQPA for 72 hours. After staining with DAPI, anti-γ-Tubulin, anti-α/β-
Tubulin, nuclei and tubulins were imaged. (B) HCT116 cells were treated with 
or without 100 nM TAK-901 or 100 nM AZD1152-HQPA for 72 hours and 
stained with PI for FACS analysis. (C) Schematic diagram of the siRNA 
screening process. HCT116 cells were plated in 1536-well plates and 
reversely transfected with siRNAs. After 24 hours, cells were treated with 
DMSO or TAK-901 for 72 hours, and cell proliferation was measured. (D) 
Cell growth in DMSO-treated plates from duplicate siRNA screens are plotted. 
The Spearman correlation coefficient is r=0.833. (E) Dot plot of Z-scores of 
siRNA screen from duplicated studies (r=0.82). Dotted line shows Z-
score=−1.2. (F) List of hit genes. Criterion for a hit gene was two siRNAs 
from the same gene with a Z-score of less than −1.2 in duplicated studies. (G) 
HCT116 cells were reversely transfected with BCL-xL siRNA for 48 hours 
and BCL-xL mRNA level was measured by TaqMan analysis. (H) HCT116 
cells were reversely transfected with BCL-xL siRNA for 24 hours, cultured 
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with 100 nM TAK-901 or 100 nM AZD1152-HQPA for 72 hours, and cell 
proliferation was measured (Student’s t-test; *, p<0.01). (I) HCT116 cells 
were reversely transfected with BCL-xL siRNA, aurora B siRNA, or their 
combination. Cell proliferation was measured 96 hours after siRNA 
transfection (Student’s t-test; *, p<0.01). BCL-xL: B-cell lymphoma-extra 
large; DAPI: 4', 6-diamidino-2-phenylindole; PI: propidium Iodide; FACS: 
fluorescence-activated cell sorting; DMSO: dimethyl sulfoxide. 
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Figure 2. Inhibition of BCL-xL with ABT-263 is sufficient for synergistic 
cytotoxicity with TAK-901.  
(A), (C) HCT116 cells were treated with 100 nM TAK-901 or 100 nM 
AZD1152-HQPA alone or in combination with 250 nM ABT-263 for 72 hours 
and cell proliferation was measured (Student’s t-test; *, p<0.01). (B), (D) 
HCT116 cells were treated with TAK-901 or AZD1152-HQPA alone in 
combination with ABT-263 at the indicated concentrations for 24 hours and 
caspase-3,7 activities was measured (Student’s t-test; *, p<0.01). (E) The 
effects of the combination of TAK-901 and ABT-263 were examined in 
several types of cancer cell lines. The combination effect was determined as 
described in the Material and Methods. (F) Table summarizing the TAK-901 + 
Cell line Tissue TAK901+ABT
SW480 CRC Synergistic
HCT 116 CRC Synergistic
SW620 CRC Some synergy
HT29 CRC Synergistic
U-87 MG Glioblastoma  Some synergy
A549 NSCLC Synergistic
NCI-H23 NSCLC Additive
NCI-H28 NSCLC Synergistic
NCI-H1299 NSCLC Additive
LNCaP Prostate Additive
NCI-H146 SCLC Additive
NCI-H196 SCLC Additive
NCI-H1395 SCLC Additive
NCI-H446 SCLC Additive
NCI-H1688 SCLC Additive
NCI-H209 SCLC Synergistic
NCI-H510A SCLC Synergistic
NCI-H1048 SCLC   Some synergy
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ABT-263 combination effect on cancer cell lines. (G) HCT116 cells were 
treated with TAK-901 and ABT-263 or gossypol for 72 hours, and cell 
proliferation was measured. CRC: colorectal cancer; SCLC: small cell lung 
cancer; NSCLC: non-small cell lung cancer. 
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Figure 3. TAK-901 increases BAX in HCT116 cells in a p53-dependent 
manner.  
(A) p53, BAX, BAK, p21, phospho-histone H3, and GAPDH were detected 
by western blotting 24 hours after TAK-901 treatment of HCT116 cells. (B), 
(C) Expression of BAK, BAX, and p53 downstream genes was detected by 
TaqMan analysis 48 hours after TAK-901 treatment of HCT116 cells 
(Student’s t-test; *, p<0.01). (D), (E) HCT116 cells were reversely transfected 
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with control or p53 siRNAs for 24 hours and treated with DMSO or 200 nM 
TAK-901 for an additional 24 hours. p53, p21, BAX, and GAPDH were 
detected by western blotting and expression of p53 downstream genes was 
detected by TaqMan analysis. (F) HCT116 cells were reversely transfected 
with control or p53 siRNAs for 24 hours and then treated with 100 nM TAK-
901 with/without 250 nM ABT-263. After 72 hours, cell proliferation was 
determined (Student’s t-test: *p<0.01). BAX: BCL2 associated X, apoptosis 
regulator; BAK: BCL2 antagonist/killer 1; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase. 
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Figure 4. BCL-xL binds to BAX and regulates BAX-dependent apoptosis 
of HCT116 cells.  
(A), (B) HCT116 and A549 cells were treated with 100 nM TAK-901 
with/without 250 nM ABT-263 for 48 hours and then lysed. Endogenous BAX, 
BCL-xL, or MCL1, were immunoprecipitated from the lysates with the 
corresponding antibody. BAX, BAK, and MCL1 in lysate input and 
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immunoprecipitated samples were detected by western blotting. (C) The 
mitochondrial fraction was separated from the cytoplasmic fraction of 
HCT116 cells after 24-hour treatment with TAK-901. BAX and GAPDH 
proteins were detected by western blotting. (D), (E) HCT116 cells were 
reversely transfected with control, BAX, or BAK siRNA. After 48-hour 
transfection, BAX and BAK mRNA levels were measured by TaqMan analysis. 
(F), (G) After 24-hour transfection, the cells were treated with TAK-901 or 
AZD1152-HQPA with/without ABT-263 for 72 hours, after which cell 
proliferation and caspase-3/7 activity were measured (Student’s t-test: 
*p<0.01). (H), (I), (J), (K) HCT116 wild-type BAX (HCT116 wt) and 
BAX−/− (HCT116 BAX null) cell lines were treated with TAK-901 or 
AZD1152-HQPA (100 nM for caspase-3/7 assay) with/without 250 nM ABT-
263. After 72 hours, cell proliferation and caspase-3/7 activity were 
determined (Student’s t-test: *p<0.01). 
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Chapter II 
 
Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to 
vulnerability in cancer cells in glucose-restricted conditions 
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Abstract 
 
Malic enzyme 1 (ME1) regulates one of the main pathways that provide 
nicotinamide adenine dinucleotide phosphate (NADPH), which is essential for 
cancer cell growth through maintenance of redox balance and biosynthesis 
processes in the cytoplasm. In this study, I found that ME1 inhibition 
disrupted metabolism in cancer cells and inhibited cancer cell growth by 
inducing senescence or apoptosis. In glucose-restricted culture conditions, 
cancer cells increased ME1 expression, and tracer experiments with labelled 
glutamine revealed that the flux of ME1-derived pyruvate to citrate was 
enhanced. In addition, cancer cells showed higher sensitivity to ME1 depletion 
in glucose-restricted conditions compared to normal culture conditions. These 
results suggest that in a low glucose environment, where glycolysis and the 
pentose phosphate pathway (PPP) is attenuated, cancer cells become 
dependent on ME1 for the supply of NADPH and pyruvate. My data 
demonstrate that ME1 is a promising target for cancer treatment, and a 
strategy using ME1 inhibitors combined with inhibition of glycolysis, PPP, or 
redox balance regulators may provide an effective therapeutic option. 
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Introduction 
 
In malignant tumours, oncogenic gene alterations such as point 
mutations, translocations, and gene amplification and deletion are recurrently 
observed, and the oncogenes and their downstream signals have been targeted 
for cancer therapy (39). In recent decades, it has become clear that cancer cells 
alter their cellular metabolism to adapt to gene and microenvironment 
alterations to sustain growth and survival (40). Therefore, targeting the 
reprogramming of cellular metabolism to treat cancers has currently come 
under the spotlight (41).  
Cancer-associated metabolic reprogramming affects gene expression, 
cellular differentiation, and tumour microenvironment, and these 
characteristics were recently summarized by Pavlova NN et al. as the six 
hallmarks of cancer metabolism (42). One hallmark corresponds to the use of 
glycolysis and tricarboxylic acid (TCA) intermediates for biosynthesis and 
nicotinamide adenine dinucleotide phosphate (NADPH) production.  
NADPH functions as a reducing agent in cells and has critical roles in 
macromolecular biosynthesis and redox homeostasis. NADPH is produced by 
metabolic enzymes such as glucose-6-phosphate dehydrogenase (G6PD) and 
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6-phosphogluconate dehydrogenase (6PGD) of the pentose phosphate 
pathway (PPP), malic enzymes (MEs), isocitrate dehydrogenases (IDHs), and 
enzymes in one-carbon-tetrahydrofolate (THF) oxidation pathways. These 
NADPH-producing enzymes have been evaluated as potential therapeutic 
targets of cancer (43–45). 
MEs regulate cellular energy, redox balance, and biomolecular 
synthesis by converting the TCA cycle intermediate malate into the TCA 
carbon source pyruvate and NADPH. In mammalian cells, three isoforms of 
MEs have been identified: a cytosolic NADP+-dependent isoform, malic 
enzyme 1 (ME1); a mitochondrial NAD+-dependent isoform, malic enzyme 2 
(ME2); and a mitochondrial NADP+-dependent isoform, malic enzyme 3 
(ME3) (46, 47). Different from the mitochondrial ME2 and ME3, ME1 
produces NADPH in the cytoplasm. It has been reported that ME1 produces 
NADPH at levels as high as those produced by G6PD in the PPP shunt, which 
is a major cellular source of NADPH (48). ME1 levels are used as a prognosis 
and predictive marker for radiation therapy in cancer (49, 50). Therefore, ME1 
is considered a promising target for cancer therapy and has been evaluated as 
such (51, 52).  
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In this study, I explored the use of ME1 as a target of cancer treatment 
through testing the vulnerability of cancer cells to ME1 inhibition by 
analyzing the resulting alterations in gene expression and metabolite levels. 
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Materials and Methods 
 
Cell lines and culture 
Human cancer cell lines were purchased from American Type Culture 
Collection (Manassas, VA, USA). HCT116 cells, HCT116 shRNA-expressing 
stable cell clones and PC3 cells were cultured in RPMI1640 (Cat. No. 22400-
089, GIBCO/ThermoFisher Scientific, Waltham, MA, USA) with 10 % FBS 
(Hyclone/GE healthcare, Chicago, IL, USA). Glucose-free or glutamine-free 
RPMI1640 medium (Cat. No. 11879020, Cat. No. 42401-018, 
GIBCO/ThermoFisher Scientific) and Glucose- and glutamine-free RPMI1640 
medium (obtained based on the components of RPMI1640 by Funakoshi, 
Tokyo, Japan) were used for isotope profiling analysis and growth assays. 
Tetracycline-free FBS (Clonetech/Takara Bio USA, Inc., Mountain view, CA, 
USA) were used with shRNA-expressing cell clones, and dialyzed FBS (Cat. 
No. 26400-044, GIBCO/ThermoFisher Scientific) were used for isotope 
profiling analysis. H460 cells were cultured in DMEM medium (Cat. No. 
11965-092, GIBCO/ThermoFisher Scientific). 
 
siRNAs, shRNAs, and reagents 
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SilencerSelect siRNAs, SilencerSelect Negative Control No. 2 
(439080846), KIF11 (s7903), ME1 (s8637, s8639), and ME2 (s8640, s8642) 
were purchased from Ambion/ ThermoFisher Scientific (Waltham, MA, USA). 
C911 siRNA was ordered and synthesized by Ambion. The C911 siRNA 
sense and antisense sequences are CCAGGUUCAAUGAGUAGUAtt and 
UACUACUCAUUGAACCUGGat, respectively. Doxycycline hyclate was 
purchased from Sigma-Aldrich (Cat. No. D9891-5G, St. Louis, MO, USA) 
and crystal violet from Wako Chemicals GmbH (Cat. No. 038-04862, Neuss, 
Germany). pTRIPZ-inducible lentiviral shRNAs for non-silencing control and 
ME1 were purchased from Open Biosystems/ GE healthcare, (Cat. No. 
RHS4743, Clone IDV2THS_151673, V3THS_322622, Chicago, IL, USA). 
 
siRNA transfection 
For siRNA experiments, cells were reversely transfected with siRNAs 
using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Waltham, 
MA, USA) according to the manufacturer's recommendations. Individual 
siRNAs were transfected at a final concentration of 10 nM.  
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Clonogenic assay 
HCT116 cells were seeded in 6-well plates at 1 000 cells/well and were 
reversely transfected with siRNAs. After siRNA transfection, cells were 
cultured for 11 days with medium changed every 3 days. Colonies were 
washed twice with phosphate buffered saline (PBS), fixed with 4 % 
formaldehyde for 15 min, and stained with crystal violet. Colony area was 
quantified by GelCount Tumor Colony Counter (Oxford Optronix, Abingdon, 
UK). 
 
Cell proliferation, cell count, caspase-3/7, and senescence analyses 
Cell viability was determined using the CellTiter-Glo luminescence 
assay (Promega, Madison, WI, USA) according to the manufacturer's 
suggested protocol. Luminescent signals were detected using an ARVO 
MX1420 microplate reader (PerkinElmer, Wellesley, MA, USA). Cell 
numbers were determined using a TC10 automated cell counter (Bio-Rad 
Laboratories, Hercules, CA, USA). In general, cancer cells were reversely 
transfected with siRNA and cell proliferation or cell numbers were determined 
96 hours after siRNA transfection. Caspase-3/7 activity was determined using 
the Caspase-Glo 3/7 Assay (Promega). Cellular senescence was assessed using 
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the SA-b-Gal Staining kit from Cell Biolabs (Cat. No. CBA-230, San Diego, 
CA, USA). 
 
Glucose and lactate assays 
Glucose and L-lactate concentrations in the medium were determined 
using LabAssay Glucose (Wako Chemicals GmbH) and L-Lactate Assay Kit 
(Colorimetric) (Abcam, Cambridge, UK), respectively. 
 
Establishment of stable pTRIPZ ME1 cell lines 
HCT116 cells were transfected with pTRIPZ vectors and selected with 
1 µg/mL puromycin 48 h after transfection. Cells were cultured in medium 
with 1 µg/mL puromycin for 14 days and grown colonies were picked up. 
Then, stably shRNA-expressing HCT116 cell clones were established. 
 
Metabolomics and isotope profiling analyses 
After siRNA or shRNA treatment, 0.5-1.0 x 106 cells were suspended in 
1 mL of 100 % methanol and centrifuged for 5 min at 15,000 x g at 4 °C. The 
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supernatant (200 μL) of cell extracts was dried by nitrogen stream and then 
derivatised by a two-step reaction: oximation and trimethylsilylation. The 
reaction mixture (1 μL) was injected into an Agilent 7890A/5975C gas 
chromatography-mass spectrometer (GC/MS) (Agilent Technologies, CA, 
USA) equipped with a J&W Scientific HP-5MS column (30 m × 0.25 mm i.d., 
film thickness = 0.25 μm, Agilent Technologies), and molecules were 
separated in a temperature gradient from 60 °C to 325 °C at 10 °C/min. The 
GC/MS data were analysed using ChemStation software (Agilent 
Technologies), and the peak areas of target molecules were exported to a 
spreadsheet for further analysis. For stable isotope tracer analysis, the 
abundances of mass isotopologues were quantified by subtracting the 
abundance of natural isotopes from the raw mass spectra (53).   
 
Statistical analyses 
All data represented the results from three independent experiments. 
The statistical differences between groups were determined using a two-tailed 
Student’s t-test. 
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Immunocytochemistry 
U2OS cells were cultured on Falcon 8 well culture slide (Corning, NY, 
USA) for 24 h and transfected with ME1, ME2 and ME3 cDNAs using 
Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells 
were stained with MitoTracker Red CM-H2Xros (ThermoFisher Scientific) 
for 30 minutes and were fixed in 4% formaldehyde in PBS for 30 minutes at 
room temperature. Then, cells were washed with PBS, permeabilized with 
cold methanol for 30 minutes at -20 °C, and treated with StartingBlock (PBS) 
blocking buffer (ThermoFisher scientific) for 1 h. Cells were incubated with 
ME1 (sc-135303, Santa Cruz), ME2 (ab191693, Abcam) or ME3 (ab172972, 
Abcam) for 1 h and then secondary antibody (Alexa Fluor 488, Abcam). 
Finally, cells were mounted with VECTASHIELD mounting medium with 
DAPI (VECTOR laboratories, Inc. Burlingame, CA, USA) and observed by a 
fluorescent microscopy. 
 
FACS analysis 
For cell size measurement using forward scatter (FSC) with fixed cells, 
PC3 cells were centrifuged at 300 rpm for 3 min, washed twice with PBS, and 
suspended in 150 μL of cold PBS. A volume of 350 μL of cold 100 % ethanol 
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was added to the cell suspensions, which were vortexed and incubated at -
20 °C for 30 min. The cells were then centrifuged at 300 rpm for 3 min, 
resuspended in PBS containing 20 ng/μL RNase A (Sigma-Aldrich), and 
incubated at 25 °C for 30 min. Next, propidium iodide (PI) was added at a 
concentration of 40 ng/μL, and cells were incubated for 10 minutes at 25 °C. 
Samples were analysed by FACS to determine cell size (using FSC) and 
distribution in the cell cycle. 
 
Quantitative RT-PCR analysis 
Cancer cells were transfected with siRNAs and, 96 h after transfection, 
total RNA was isolated from cells and purified with the RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to manufacturer's instructions. 
Quantitative real-time PCR analysis was performed on a ViiA7 (Applied 
Biosystems, Foster City, CA, USA), using TaqMan Fast Advanced Master 
Mix with TaqMan probes against the indicated genes (Applied Biosystems). 
Data were analysed according to the 2–ΔΔCt method and normalised relative to 
the amount of GAPDH mRNA. The normalised abundance of target mRNAs 
was expressed relative to the corresponding values for cells treated with 
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dimethyl sulphoxide or negative control siRNAs. The following TaqMan 
probes were used for quantitative RT-PCR analysis: ME1 (Hs01554892_m1), 
ME2 (Hs00929809_g1), ME3 (Hs00198572_m1), G6PD (Hs00166169_m1), 
6PGD (Hs00427230_m1), IDH1 (Hs01855675_s1), IDH2 (Hs00158033_m1), 
MTHFD1 (Hs01068263_m1) and  MTHFD2 (Hs00759197_s1), CDKN1A 
(Hs00355782_m1), CDKN1B (Hs01597588_m1), CDKN2A 
(Hs00923894_m1), HMOX-1 (Hs01110250_m1), TP53 (Hs01034249_m1), 
PDHA1 (Hs01049345_g1), PDHB (Hs00168650_m1), GAPDH 
(Hs99999905_m1), and 18SrRNA (Hs99999901_s1).   
 
Western blotting 
Whole cell extracts were prepared with 1 x Laemmli sample buffer 
(Tris-HCl 125 mM pH 7.5, 1 % SDS, 20 % glycerol). The extracts were 
fractionated by SDS-PAGE, and the separated proteins were transferred using 
an iBlot Transfer Stack (Nitrocellulose) and an iBlot Gel Transfer Device 
(Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA). After incubation 
with StartingBlockT20 (PBS) blocking buffer (Pierce Biotechnology, 
Rockford, IL, USA), the membranes were labelled for approximately 16 h 
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with primary antibodies, followed by incubation with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology, Beverly, MA, 
USA). Membranes were incubated with ImmunoStar Zeta (Wako Chemicals 
GmbH) and scanned using an ImageQuant LAS-3000 (Fujifilm, Tokyo, 
Japan). The following antibodies were used for western blotting analysis: 
ME1 (H-47) (sc-135303) and actin (C-2) (sc-8432) from Santa Cruz, HO-1 
(HMOX-1) (ADI-SPA-896) from Enzo Life Sciences (Farmingdale, NY, 
USA). 
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Results 
 
ME1 localises in the cytosol and is expressed in various cancer cell lines 
To identify the localisation of MEs in cancer cells, I conducted 
immunocytochemistry (ICC). U2OS cells were transfected with ME1, ME2, 
or ME3 cDNAs and immuno-stained with each antibody; mitochondria were 
stained with MitoTracker. As previously reported89, ME1 localised in the 
cytoplasm, whereas ME2 and ME3 localised in the mitochondria (Figure 5A). 
I conducted TaqMan analysis to investigate the expression profile of malic 
enzymes in cells of various cancer types. I found that most cancer cell lines 
express higher levels of ME1 than of ME2 and ME3, although some cell lines 
predominantly expressed ME2 and ME3 (Figure 5B). Therefore, I examined 
the effects of ME1 inhibition on cancer cell proliferation and metabolism. 
 
ME1 knock down suppresses cancer cell growth and induces senescence 
To examine the effects of ME1 or ME2 inhibition on HCT116 cell 
growth, I performed knock down experiments using siRNAs. I excluded ME3 
siRNA because ME3 mRNA was not detected in HCT116 cells (Figure 5B). 
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Both ME1 and ME2 mRNA and protein levels were suppressed by siRNAs 
(Figure 7A and 7B). ME1 depletion suppressed colony formation in 
clonogenic assays (Figure 6B and 6C), whereas ME2 depletion did not affect 
HCT116 cell growth. Some colonies of cells transfected with ME1-1 siRNA 
included enlarged cells (Figure 6D), which is a hallmark of senescent cells 
(54). To confirm these observations, I repeated the experiments with the PC3 
cell line. I first examined if ME1 depletion affected PC3 cell growth. ME1 
expression was suppressed by the two siRNAs in PC3 cell line (Figure 7D). In 
this condition, I found that ME1 depletion suppressed PC3 cell proliferation 
96 h after siRNA reverse-transfection (Figure 6D). Next, I conducted 
clonogenic assays with the PC3 cell line. PC3 cells were reversely transfected 
with siRNAs and cultured for nine days. FACS analysis revealed that the 
number of enlarged PC3 cells increased after transfection with ME1 siRNAs 
(Figure 6E), which is consistent with microscopic observation of colonies 
(Figure 7E). I investigated the expression of SA-β-Gal, which is another 
hallmark of senescence, in the PC3 colonies and found some SA-β-Gal 
positive cells (Figure 5F, blue staining). I manually counted SA-β-Gal stain-
positive and -negative PC3 cells and calculated the percentage of stained cells. 
The results show that the number of SA-β-Gal stain-positive cells clearly 
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increased after ME1 knock down (Figure 5G). These results suggest that ME1 
depletion induces cellular senescence and suppresses cancer cell growth. 
 
ME1 knock down disturbs malate levels and its downstream metabolism 
in the HCT116 cell line 
To examine the metabolic alterations resulting from ME1 depletion, I 
conducted a tracer experiment with [U-13C, U-15N] L-glutamine in the 
HCT116 cell line. The flow of the isotopic glutamine tracer is shown in Figure 
8A. Incorporated [U-13C, U-15N] L-glutamine is metabolised to fumarate 
(m+4) and malate (m+4) in mitochondria through oxidative glutaminolysis 
and TCA cycle reactions. A portion of malate (m+4) becomes oxaloacetate 
(m+4) and citrate (m+4) through consecutive TCA cycle reactions in 
mitochondria. Another portion of malate (m+4) is exported to the cytoplasm 
from mitochondria and is converted into pyruvate (m+3) by ME1. Pyruvate 
(m+3) is converted into acetyl-CoA (m+2) in mitochondria, which then 
generates citrate (m+2) or citrate (m+6) (Figure 8A). In the experiment, I used 
ME1-1 siRNA, which suppressed ME1 expression but not cell growth 96 h 
after transfection, as a control to exclude metabolic changes caused by cell 
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growth inhibition. Malate (m+4) and fumarate (m+4) were found to be 
accumulated after ME1 knock down. Although pyruvate (m+3) levels were 
not reduced, both citrate (m+2) and citrate (m+6) levels decreased, whereas 
citrate (m+4) levels did not change (Figure 8B and 10A). These results 
suggest that the supply of pyruvate (m+3) and subsequently of acetyl-CoA 
(m+2) are reduced after ME1 knock down without affecting TCA cycle 
reactions. I conclude that ME1 knock down suppresses malate levels and its 
downstream metabolism in the HCT116 cell line. 
 
ME1 inhibition induces metabolic reprograming and disturbs redox 
homeostasis in cancer cell lines 
To investigate the effect of ME1 inhibition on cellular metabolism, I 
conducted metabolomics analysis in HCT116 cell lines after ME1 knock down. 
I detected some metabolite level changes 48 hours or 72 hours after siRNAs 
transfection. Consistent with isotope profiling experiments (Figure 8B), 
malate and fumarate levels increased after ME1 depletion (Figure 9A and 
10B). Intriguingly, the levels of glucose-6-phosphate (G6P) and ribose-5-
phosphate (R5P), which are metabolites in PPP, also increased after ME1 
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depletion (Figure 9B). Furthermore, pyruvate and lactate levels increased 
significantly after ME1 inhibition (Figure 9C). These results suggest that 
glycolysis and PPP are enhanced as a result of ME1 inhibition in HCT116 
cells. Because ME1 inhibition induced cellular metabolic reprograming, I 
speculated that ME1 depletion induces some cellular response. Therefore, I 
investigated the expression of NADPH-producing enzymes and senescence-
related genes in HCT116 and PC3 cells. ME1 depletion increased CDKN1A 
and HMOX-1 (HO-1) mRNA levels (without affecting expression of other 
NADPH-producing enzymes in the PC3 cell line, Figure 9D), and the same 
result was observed in ME1-depleted HCT116 cells (Figure 10C and 10D). To 
verify that CDKN1A and HO-1 expression were induced by ME1 inhibition, I 
examined CDKN1A and HO-1 protein expression in HCT116 cells using 
C911ME1 siRNA (55), which is similar in sequence to ME1 siRNA but was 
designed to remove gene knock down ability, as a negative control. I also 
examined whether the presence of glucose could affect expression of 
CDKN1A and HO-1. The results show that CDKN1A and HO-1 protein levels 
increased after ME1 inhibition and the phenotypes were reverted by C911 
(Figure 9E), suggesting that ME1 knock down stimulates CDKN1A and HO-1 
expression in HCT116 cells. Furthermore, I found that HO-1 expression was 
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enhanced in glucose-depleted condition but that of CDKN1A was not (Figure 
9E). These results suggest that ME1 inhibition disturbs redox homeostasis by 
regulating glucose metabolism. 
In the H460 cell line, which shows high levels of ME1 expression 
(Figure 5B), HO-1 expression was enhanced and cell growth was inhibited by 
ME1 inhibition as observed in HCT116 and PC3 cells (Figure 10E and 10F), 
although I did not observe senescence-like cells even in a clonogenic assay 
(data not shown). On the other hand, caspase-3,7 activity was augmented by 
ME1 knock down in H460 cell lines, indicating that ME1 inhibition induced 
apoptosis in H460 cells (Figure 10G). These results suggest that ME1 
inhibition disturbs cellular metabolism and redox balance in several cancer 
cell lines but the specific phenotype, such as senescence or apoptosis, varies in 
each cell line. 
 
Glucose depletion increases reductive carboxylation and enhances ME1-
dependent glutamine metabolism in HCT116 cells 
I found that ME1 inhibition affected glucose metabolism, and that 
glucose concentration in the medium affected HO-1 expression induced by 
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ME1 inhibition in HCT116 cells. Therefore, I investigated whether glucose 
availability affected malate metabolism and expression. I first conducted cell 
growth assays in glucose-restricted conditions. HCT116 cells were cultured in 
RPMI1640 media with 0, 0.2, 0.5, 1, and 2 g/L glucose, and cell viability was 
measured after 24, 48, and 72 hours (normal medium contains 2 g/L glucose). 
Compared to 2 g/L glucose, HCT116 cell growth was suppressed after 48 h in 
0.2 g/L, slightly suppressed after 72 hours in 0.5 g/L, and suppressed in less 
than 24 h in glucose free (0 g/L) medium (Figure 11A).  
 To monitor metabolic alterations in cells in glucose-depleted conditions, 
I performed a tracer experiment with [U-13C, U-15N] L-glutamine in the 
presence or absence of glucose in the medium. No difference in glutamine 
incorporation or malate (m+4) content was found; however, pyruvate (m+3), 
citrate (m+6), and lactate (m+3) levels increased (Figure 11B), suggesting that 
malate (m+4) metabolism is enhanced in glucose-depleted conditions. 
Furthermore, malate (m+0) and citrate (m+0) levels decreased in glucose-free 
conditions, suggesting that glucose-derived metabolites are reduced in cells. 
Malate (m+3) levels increased in glucose-free conditions, which may be due 
to activation of reductive carboxylation of glutamine. Reductive carboxylation 
produces citrate (m+5) from glutamine (m+7) and results in production of 
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malate (m+3) through TCA cycle reactions (Figure 8A). Production of malate 
(m+3) results in an increase in downstream metabolites such as pyruvate 
(m+2) and lactate (m+2) (Figure 11B). 
To examine the effects of glucose-restricted conditions on the 
expression of NADPH-producing enzymes, mRNA expression levels of ME1, 
ME2, G6PD, 6PGD, IDH1, and IDH2 were determined in HCT116 cells 
cultured in glucose-restricted media for 24, 48, and 72 hours. Expression 
levels of NADPH-producing enzymes except ME1 decreased in a glucose 
concentration dependent manner, whereas ME1 expression levels remained 
unchanged regardless of glucose concentration. These results suggest that 
HCT116 cells depend in part on ME1 in glucose-restricted conditions (Figure 
11C). I conclude that glucose depletion induces reductive carboxylation 
instead of glycolysis and enhances ME1-dependent glutamine metabolism in 
HCT116 cells. 
 
ME1 knock down synergistically suppress HCT116 cell growth in 
glucose-depleted conditions 
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My experiments suggested that malate metabolism and glycolysis are 
coordinately regulated to maintain cellular redox homeostasis. I next 
examined whether ME1 inhibition synergistically suppressed cell growth in 
glucose-depleted conditions. I initially established shRNA tetracycline-
inducible HCT116 cell clones, which expressed different shRNA sequences 
(sh control, sh ME1-1 or sh ME1-2) when induced by doxycycline. ME1 
mRNA levels were suppressed 48 hours after doxycycline treatment in 
HCT116 clones (Figure 12A). I also examined ME1 protein expression in sh 
control, sh ME1-1, and sh ME1-2 clones cultured for 48 hours or 72 hours 
with or without doxycycline in 2 g/L or 0.5 g/L glucose. ME1 expression was 
suppressed by ME1 shRNA regardless of glucose concentration (Figure 13A 
and 13B). In contrast, ME2 mRNA expression levels remained unchanged 
after doxycycline treatment (Figure 13C). Cell proliferation was partially 
suppressed by ME1 shRNA induction in HCT116 clones (Figure 12B). I 
determined D-glucose and L-lactate concentrations in the media in which sh 
control, sh ME1-1, or sh ME1-2-transfected cells were cultured for 96 h with 
or without doxycycline. Statistically significant decrease in D-glucose levels 
and increase in L-lactate levels were observed after ME1 shRNA induction 
(Figure 12C), suggesting that glycolysis is activated by ME1 inhibition in 
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these clones. I next conducted a tracer experiment with [U-13C, U-15N] L-
glutamine in HCT116 clones under glucose-depleted conditions. I initially 
determined if doxycycline affected cellular metabolism in the sh control clone, 
and found that doxycycline did not affect metabolite levels in glucose-
sufficient or -depleted conditions (Figure 13E). In sh ME1-1 and sh ME1-2 
clones, accumulation of malate (m+4) and lactate (m+0) and reduction of 
citrate (m+2) were observed in both clones after ME1 knock down (Figure 
12D and 13D), indicating that malate metabolism is suppressed and glycolysis 
is activated in these clones. I also observed significant reduction in NADPH 
levels after ME1 knock down in sh ME1 clones (Figure 12E), suggesting that 
redox balance is disturbed in these clones. To investigate the effect of ME1 
depletion on cell growth in glucose-depleted conditions, I conducted cell 
growth assays with these clones under these conditions. HCT116 clones were 
treated with or without doxycycline and cultured for 24 hours in normal 
culture conditions. Clones were then cultured for 96 hours in normal (2 g/L) or 
0.5 g/L glucose medium. ME1 knock down significantly suppressed cell 
growth in glucose-restricted compared to normal culture conditions, indicating 
that glucose-depletion and ME1 inhibition have a synergistic effect in 
HCT116 cell clones (Figure 12F and 14C). Similar results were observed in an 
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additional clone (Figure 14A and 14B). In contrast, glucose-restricted 
conditions did not synergistically suppress cell growth of a non-ME1 silencing 
control clone (Figure 12F and 14C). These results suggest that ME1 knock 
down synergistically inhibits HCT116 cell growth in glucose-depleted 
condition. 
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Discussion 
 
NADPH production is regulated by multiple metabolic pathways to 
maintain cellular energy, reducing equivalents, and biomolecules. Cancer cells 
regulate NADPH homeostasis through multiple pathways such as the PPP and 
the flux through ME1 and IDH1 in the cytoplasm. Recently, stepwise 
oxidation of one-carbon-THF species was also reported to have a role in 
cellular NADPH production (56).  
ME1 metabolism is known to be regulated by well-known oncogenes or 
tumour suppressors such as K-ras, myc, or p53 (44, 51). Furthermore, ME1 is 
reported to be a potential prognostic or sensitivity marker of radio therapy (49, 
50). My ICC study revealed that ME1 localised in the cytosol, whereas ME2 
and ME3 localised in the mitochondria, which is consistent with previous 
findings (46, 47). I found that ME1 is highly expressed in most cancer cell 
lines compared to ME2 and ME3, although some cell lines predominantly 
expressed ME2 or ME3. Taken together, these findings suggest that ME1 has 
an important function in the growth and survival of cancer cells and that it 
could be a target for cancer therapy.  
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The ME1 knock down experiments described here revealed that ME1 
depletion does not induce acute cell growth inhibition, but suppresses cancer 
cell growth gradually by inducing senescence in HCT116 and PC3 cell lines 
or apoptosis in H460 cell line. Partial cell growth inhibition was also observed 
in other cancer cell lines (Table 1). I demonstrated that ME1 knock down 
increased the expression of HMOX-1 (HO-1), which is an oxidative stress 
marker regulated by Nrf2 (57), suggesting that ME1 depletion disturbs 
metabolic and redox balance in cancer cells. I speculate that ME1 depletion 
suppresses cancer cell growth by abrogating metabolic and redox balance in 
the cancer cells, and the specific phenotype such as senescence, apoptosis, or 
others, depends on cellular context in each cell line. I need further studies to 
identify cell fate determinants in ME1-suppressed cancer cells, which could be 
sensitivity markers for a ME1 inhibitor in clinical settings. 
L-glutamine isotope profiling analysis revealed the metabolic 
alterations in cancer cells by ME1 knock down. Accumulation of malate 
(m+4) and fumarate (m+4) implies inhibition of the malate flux by ME1 
knock down. Reduction in citrate (m+2) and citrate (m+6) levels, but not in 
citrate (m+4) levels, indicates that the malate-pyruvate-acetyl-CoA flux is also 
suppressed by ME1 knock down. Although pyruvate (m+3) reduction was 
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expected after ME1 knock down, no significant changes in pyruvate levels 
were observed. This may be due to pyruvate (m+3) being immediately 
converted to acetyl-CoA and the malate-to-pyruvate conversion being rate-
limiting in cells. Basal pyruvate levels would thus be kept low, and a 
reduction would be difficult to detect.  
Pyruvate accumulation was observed in our metabolomics analysis 
(Figure 9C). I also observed lactate accumulation by ME1 siRNA (Figure 9C) 
and ME1 shRNAs (Figure 12D) which may be caused by upregulation of 
glycolysis. Increase of R5P and G6P levels supports this hypothesis (Figure 
9B). I also found that glucose levels decreased and lactate levels increased in 
the media after ME1 knock down in HCT116 cells (Figure 12C), suggesting 
that the Warburg Effect is enhanced by ME1 inhibition in HCT116 cells. I 
demonstrated that ME1 knock down induced HO-1 expression, a marker of 
oxidative stress (Figure 9D and 9E). Cancer cells may enhance glycolysis after 
ME1 depletion to compensate for the reduction in NADPH by activating PPP 
in the cytoplasm and may adapt to an oxidative state for protection. HO-1 
expression after ME1 inhibition was higher in glucose-depleted compared to 
glucose-sufficient conditions (Figure 9E), suggesting that glycolysis may 
relieve the oxidative state in HCT116 cells. Alternatively, because pyruvate is 
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known to have antioxidative function (58, 59), cancer cells may manage the 
oxidative state by increasing pyruvate levels in addition to the activation of the 
PPP pathway.  
Although both si ME1-1 and si ME1-2 suppressed ME1 expression at 
mRNA and protein levels (Figure 7A and 7B) and both enhanced malate 
accumulation (Figure 9A), which is a target engagement marker of ME1 
inhibition, si ME1-2 showed stronger cell growth inhibition than si ME1-1. I 
believe that si ME1-2 has an off-target effect in addition to ME1 inhibition. 
Enhanced accumulation of pyruvate and lactate by si ME1-2 compared to si 
ME1-1 may be caused by this off-target effect.  
I demonstrated that ME1 inhibition induces metabolic reprogramming 
and abrogates redox balance in cancer cells, both being related to glucose 
metabolism. Therefore, I investigated if glucose concentration in the media 
could affect cellular malate metabolism and malic enzyme levels. Isotope 
profiling analysis indicated that cellular metabolic balance is changed from 
glycolysis-dependent to glutaminolysis-dependent in glucose-depleted 
conditions (Figure 11B). Malate (m+0) levels decreased in glucose-free 
conditions because of the reduction in glucose-derived metabolites. Decrease 
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in citrate (m+0) levels supports this hypothesis. The increase in malate (m+3) 
levels in glucose-free conditions may be due to activation of reductive 
carboxylation of glutamine. Reductive carboxylation produces citrate (m+5) 
from glutamine (m+7) and results in the production of malate (m+3) through 
TCA cycle reactions. Increase of malate (m+3) results in increase of pyruvate 
(m+2) and lactate (m+2). Malate (m+4) levels are similar between normal 
glucose and glucose-free conditions. However, pyruvate (m+3) and citrate 
(m+6) were observed only in cells cultured in glucose-free media, suggesting 
that ME1 activity could be induced in cancer cells under glucose-depleted 
condition. ME1 expression did not decreased in glucose-depleted conditions, 
although the levels of other NADPH-producing enzymes decreased (Figure 
11C), which suggests that cancer cells depend in part on ME1 in glucose-
depleted conditions. Here, I demonstrated that HCT116 cells increase its 
dependency on ME1 metabolism in glucose-depleted conditions. 
From these results, I speculated that ME1 inhibition would 
synergistically inhibit cancer cell growth in glucose-depleted conditions. To 
address the hypothesis, I established ME1 shRNA-inducible HCT116 cell 
lines, which showed similar metabolic changes to HCT116 cells transfected 
with ME1 siRNA under ME1 shRNA induction in glucose-depleted 
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conditions (Figure 12D). Expression of ME1 mRNA in sh ME1 clones were 
lower than that of sh control clones, which may be due to leak of ME1 shRNA 
in the clones. These results may also explain the higher glucose consumption 
and higher lactate production in ME1 shRNA clones than those in sh control 
clones (Figure 12A and 12C). I demonstrated that combining ME1 inhibition 
with glucose-depletion synergistically inhibited cancer cell growth. I did not 
observe any cells with senescence-like or apoptotic phenotypes in these cells. 
Senescence-like phenotype similar to that shown in Figure 6F could be 
observed if shRNA-expressing cells were cultured for a much longer period in 
normal media. However, cells died earlier in glucose-depleted than in glucose-
sufficient conditions, suggesting that another cell killing mechanism was 
activated by combining ME1 inhibition and glucose depletion. The oxidative 
state, indicated by a reduction in NADPH levels, may result in cell growth 
inhibition. Additional studies such as rescue of growth inhibition by 
antioxidants would test this hypothesis.  
An in vivo efficacy study is needed to verify whether ME1 inhibition is 
effective as a tumour growth suppressor. It is known that glucose levels are 
depleted within the tumour, although the tumour-induced angiogenesis, which 
provides nutrients (including glucose) to support rapid growth, may lead to 
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higher levels of intra-tumour glucose than expected. Therefore, the efficacy of 
ME1 inhibition on tumour growth suppression probably depends on the 
tumour microenvironment, and in vivo experiments are necessary to clarify the 
issue. I hypothesise that a treatment strategy combining an ME1 inhibitor with 
an inhibitor of glycolysis, such as 2-DG, or with an inhibitor of glucose 
transporter, such as GLUT-4 inhibitor, could result in a synergic action against 
the tumour regardless of tumour microenvironment. 
ME1 inhibition may be toxic in some tissues, as ME1 is ubiquitously 
expressed. Tumours sensitive to ME1 inhibition should therefore be selected. 
For example, ME1 expression is known to be regulated by Nrf2, and tumours 
with mutated Keap1 or Nrf2 genes could be dependent on ME1 and thus be 
sensitive to ME1 inhibition. Alternatively, as described above, a glucose-
depleted microenvironment could make tumours sensitive to ME1 inhibition. 
In this study, I demonstrated that ME1 is an essential enzyme that 
regulates cellular metabolism and redox balance. I also showed that, in 
glucose-depleted conditions, cancer cells become dependent on the ME1 flux 
to produce NADPH and pyruvate and to manage redox homeostasis, 
suggesting that these cells become vulnerable to reduced ME1 activity. Taken 
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together, my results demonstrate that ME1 inhibition suppresses cancer cell 
growth and induces apoptosis or senescence depending on the cellular context, 
consistent with previous reports (44, 51, 52), and that tumours in a nutrient-
limited microenvironment are a sensitive target for ME1 inhibition. No ME1 
inhibitors are currently being evaluated in clinical trials, although a few small-
molecule ME2 inhibitors were discovered in pre-clinical trials (60–62). A 
treatment strategy combining ME1 inhibitors with inhibition of glycolysis, 
NADPH-producing enzymes, or redox-regulating enzymes would provide an 
effective therapeutic option for some types of cancer. Further work is required 
in animal models to assess if such a strategy would be effective in tumours. 
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Figure 5. ME1 localises in the cytosol and is expressed in cancer cell lines.  
(A) U2OS cells were transfected with ME1, ME2, or ME3 cDNA plasmid and, 
48 hours later, cells were fixed and stained with DAPI, anti-ME1, anti-ME2, 
and anti-ME3 antibodies, and Mito-tracker, which specifically stains 
mitochondria. Nucleus (blue), ME1, ME2, or ME3 (green), mitochondria (red) 
and the merged image are shown. (B) Basal ME1, ME2, and ME3 mRNA 
expression levels in colorectal, ovarian, lung, and pancreatic cancer cell lines 
were determined by TaqMan PCR. Expression levels were normalised by 
expression of α-actin in each cell line and the relative expression is shown in 
the bar graph (n=3). 
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Figure 6. ME1 knock down induces cellular senescence and suppresses 
cell growth.  
(A, B) HCT116 cells were reversely transfected with control, ME1, or ME2 
siRNAs and 1,000 cells were seeded on 6-well plates. Then, cells were 
cultured for 11 days for colony formation assay. Colonies were fixed and 
stained with Crystal violet, and colony area of each well was quantified by 
GelCount and relative total area is shown as a bar graph (n=3, mean with SD). 
(C) Light microscopy images of colonies of HCT116 cells transfected with si 
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control and si ME1-1. (D) PC3 cells were transfected with ME1 siRNAs and 
viability was determined 96 hours after transfection. Relative cell proliferation 
is shown as a bar graph (n=3, mean with SD). (E) PC3 cells were transfected 
with ME1 siRNAs and cultured for 96 hours. Cell size (FSC) was detected by 
FACS analysis. (F) PC3 cells were transfected with ME1 siRNAs for 9 days 
and β-galactosidase was then stained. Cell (outer white line) and its nucleus 
(inner white line) are shown in the upper photograph. β -galactosidase was 
stained in blue and is shown in the lower photograph. (G) β -galactosidase-
positive cells were manually counted and the percentage of stain-positive (SA-
β-Gal positive) cells are shown in the bar graph. 
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Figure 7. ME1 knock down suppresses cell growth. 
(A) ME1 and ME2 mRNA levels were normalised by GAPDH and are shown 
in the bar graph. HCT116 cells were reversely transfected with control, ME1, 
or ME2 siRNAs, and RNAs were collected 48 hours after transfection. ME1 
and ME2 expression were determined by TaqMan analysis (n=3). (B) 
Expression of ME1, ME2, and α-actin in HCT116 cells were detected by 
western blotting. Cell lysate was collected 48 hours after transfection with the 
indicated siRNAs. (C) HCT116 cells were reversely transfected with indicated 
siRNAs for 96 hours. Cell proliferation was determined by CellTiter Glo 
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(n=3). (D) Expression of ME1 and α-actin in PC3 cells were determined by 
western blotting. Cell lysate was collected 48 hours after transfection with the 
indicated siRNAs. (D) Light microscopy images of colonies of PC3 cells 
transfected with control and ME1 siRNAs and cultured for 9 days.  
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Figure 8. [U-13C, U-15N] L-glutamine isotope profiling analysis revealed 
malate metabolism is suppressed by si ME-1.  
(A) Schematic representation of glutamine isotope profiling. Blue and purple 
circles indicate a carbon isotope, metabolized through oxidative 
glutaminolysis and reductive carboxylation, respectively, pink circles a 
nitrogen isotope, and white circles non-labelled carbons. (B) [U-13C, U-15N] 
L-glutamine profiling analysis was performed in the HCT116 cell line. Cells 
were cultured for 72 hours after siRNA transfection and labelled for 24 hours 
in McCoy's 5A media with 2 mM [U-13C, U-15N] L-glutamine. Cell pellets 
were then collected for flux analysis. Peak area of each metabolite is shown in 
the dot graph (n=3, t-test; *, p<0.01; #, p<0.05).  
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Figure 9. ME1 knock down disturbs metabolic homeostasis and induces 
oxidative stress response in cancer cells.  
(A, B, C) Metabolomics analysis was conducted 48 and 72 hours after ME1 
siRNAs transfection in HCT116 cells. Peak area of malate, ribose-5-phosphate, 
glucose-6-phosphate, pyruvate, and lactate are shown in the dot graph (n=3, t-
test; *, p<0.01; #, p<0.05). (D) Gene expressions of NADPH-producing 
enzymes, p53-related enzymes, a redox-related gene, and glycolysis-relating 
enzymes were detected by TaqMan PCR 48 hours after ME1 siRNAs 
transfection in PC3 cells (n=3). (E) ME1, HO-1, and α-actin were detected by 
western blotting 96 hours after control siRNA, ME1 siRNAs, or ME1 C911 
transfection in HCT116 cells (ME1 is indicated by a black arrow). After 
siRNA transfection, cells were cultured in 2 g/L glucose McCoy's 5A media 
for 72 hours, cultured in media with/without glucose for further 24 hours, and 
then the cell lysate was collected for western blotting. 
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Figure 10. ME1 knock down disturbs metabolic homeostasis, induces 
oxidative stress response and apoptosis in cancer cells. 
(A) Additional metabolite graphs of the experiments described in Figure 8A 
(n=3, t-test; *, p<0.01; #, p<0.05). (B) Additional metabolite graphs of the 
experiments described in Figure 9A-9C (n=3, t-test; *, p<0.01; #, p<0.05).  
(C) Relative mRNA expression levels of NADPH-producing enzymes under 
ME1 knocked down condition in HCT116 cells. mRNA levels were 
determined 48 and 72 hours after siRNA transfection. Expression of indicated 
genes was normalised by GAPDH and relative expressions are shown in the 
bar graph (n=3). (D) CDKN1A and HO-1 mRNA expression levels in HCT116 
cells were determined by TaqMan analysis. mRNAs were extracted from 
HCT116 cells 72 hours after control and ME1 siRNAs transfection. 
Expression of CDKN1A and HO-1 was normalised by GAPDH and relative 
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expression levels are shown in the bar graph (n=3). (E) Expression of ME1, 
HO-1, and α-actin detected by western blotting 96 hours after control siRNA, 
ME1 siRNAs, or ME1 C911 transfection in H460 cells. After siRNA 
transfection, cells were cultured for 96 hours and cell lysate was collected for 
western blotting. (F) Cell numbers were determined 96 hours after siRNAs or 
C911 transfection in H460 cells. Cell number per mL is shown in the bar 
graph (n=3, t-test; #, p<0.05). (G) Caspase-3,7 activity was determined 96 
hours after siRNA or C911 transfection in H460 cells. Relative caspase-3,7 
activity is shown in the bar graph (n=3, t-test; *, p<0.01; #, p<0.05). 
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Figure 11. Glucose depletion increases ME1-dependent glutamine 
metabolism and reduces expression of NADPH-producing enzymes other 
than ME1 in HCT116 cells.  
(A) HCT116 cells were cultured in glucose-depleted or -limited media (2, 1, 
0.5 or 0.2 g/L glucose or glucose-free) for 72 hours. Cell viability was 
determined at 24, 48, and 72 hours using CellTiter Glo. Relative cell growth, 
normalised by cell viability at Day 0, is shown in the line graph (n=3, t-test; *, 
p<0.01). (B) HCT116 cells were cultured in media with or without glucose for 
24 hours and labelled with [U-13C, U-15N] L-glutamine isotope for an 
additional 24 hours. Then, isotope profiling analysis was conducted. 
Percentage of the pool of metabolites and isotopes is shown in the bar graph (2 
g/L glucose in black and glucose-free in white; n=3, mean with SD). (C) 
HCT116 cells were cultured in media with 2, 1, 0.5, or 0.2 g/L glucose for 72 
hours and mRNA expression levels of NADPH-producing enzymes at 0, 24, 
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48, and 72 hours were determined by TaqMan PCR and are shown in the line 
graph (n=3). 
  
97 
 
 
*
*
*
*
sh Cont sh ME1-1 sh ME1-2
A B C
0
0.2
0.4
0.6
0.8
1
1.2
R
el
at
iv
e 
M
E1
 E
xp
re
ss
io
n
Dox -
Dox +
D
F
E
* *
*
*
* *
Lactate (m+0)
-
D
ox
-
D
ox
0
500000
1000000
1500000
sh ME1-1 sh ME1-2
* *
Pe
ak
 A
re
a
NADPH
-
D
ox
-
D
ox
0
5000
10000
15000
20000
Clone 38 Clone 44
# #
Pe
ak
 A
re
a
Malate (m+4)
-
D
ox
-
D
ox
0
5000
10000
15000
20000
25000
Clone 38 Clone 44
*
*
Pe
ak
 A
re
a
Citrate (m+2)
-
D
ox
-
D
ox
0
1000
2000
3000
4000
5000
Clone 38 Clone 44
*
*
Pe
ak
 A
re
a
98 
 
Figure 12. ME1 knock down by shRNA induces metabolic reprograming 
and synergistically suppresses cancer cell growth in glucose-depleted 
conditions.  
HCT116 cell clones (sh ME1-1 and sh ME1-2), which are stably expressing 
tetracycline-inducible ME1 shRNA, were established. (A) Control shRNA, sh 
ME1-1, or sh ME1-2 clones were cultured in the media with or without 2 
µg/mL doxycycline for 48 hours, and ME1 expression was detected by 
TaqMan PCR. ME1 expression was normalised by GAPDH expression and 
relative ME1 expression is shown in the bar graph (n=3). (B) Cell numbers 
were determined 72 hours with or without 2 µg/mL doxycycline. Relative cell 
number is shown in the bar graph (n=3, mean with SD, t-test; *, p<0.01) (C) 
Control shRNA, sh ME1-1, or sh ME1-2 were cultured in the media with or 
without 2 µg/mL doxycycline for 96 hours and, D-glucose and L-lactate 
concentration in the media were measured. Relative glucose or lactate 
concentration are shown in the bar graph (n=3, mean with SD, t-test; *, 
p<0.01). (D, E) [U-13C, U-15N] L-glutamine isotope profiling analysis was 
conducted in sh ME1-1 and sh ME1-2 clones. Clones were cultured in the 
media with 2 g/L glucose with or without doxycycline for 72 hours and 
labelled for additional 24 hours in the glucose-depleted media with or without 
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doxycycline. Then, metabolites and isotopes were measured. Peak area of 
labelled metabolites are shown in the dot graphs (n=3, t-test; *, p<0.01; #, 
p<0.05). (E) Three clones were cultured for 24 hours in 2 g/L medium with or 
without doxycycline, and additionally cultured for 72 hours in medium with 2 
g/L or 0.5 g/L glucose with or without doxycycline. Then, cell numbers were 
determined by cell counter (n=3, mean with SD; t-test; *, p<0.01). 
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Figure 13. ME1 knock down by shRNA induces metabolic reprograming 
in glucose-depleted conditions. 
(A, B) ME1 and α-actin expression determined by western blotting in sh 
control, sh ME1-1 and sh ME1-2 clones. Clones were cultured with or without 
2 µg/mL doxycycline for 48 hours or 72 hours in media with 2 g/L or 0.5 g/L 
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glucose. (C) Relative ME2 expression determined in shRNA clones cultured 
with or without 2 µg/mL doxycycline for 48 hours (n=3). (D) Additional 
metabolite graphs of the experiments described in Figures 12D and 12E (n=3, 
t-test; *, p<0.01). (E) Metabolomics analysis conducted in the sh control clone. 
The sh control clone was cultured in the media with 2 g/L glucose with or 
without doxycycline for 72 hours and cultured for an additional 24 hours in 
the media with 2 g/L glucose or glucose-free with or without doxycycline. 
Then, metabolites and isotopes were measured. Peak area of labelled 
metabolites are shown in the dot graphs (n=3).  
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Figure 14. ME1 knock down by shRNA synergistically suppresses cancer 
cell growth in glucose-depleted conditions. 
(A) Relative ME1 and ME2 expression levels determined in sh control and a 
ME1-2 shRNA clone (clone 65). The clones were cultured for 48 hours with 
or without 2 µg/mL doxycycline and RNAs were extracted. mRNA expression 
levels were determined by TaqMan analysis and normalised by GAPDH 
mRNA levels (n=3). (B) sh control and clone 65 were cultured for 24 hours in 
2 g/L medium with or without doxycycline, and additionally cultured for 72 
hours in medium with 2 g/L or 0.5 g/L glucose with or without doxycycline. 
Cell numbers were determined by cell counter (n=3, t-test; *, p<0.01). (C) 
Light microscopy images of HCT116 sh control, sh ME1-1, sh ME1-2, and 
clone 65. The clones were cultured for 24 hours in 2 g/L medium with or 
without doxycycline, and additionally cultured for 72 hours in medium with 2 
g/L or 0.5 g/L glucose with or without doxycycline. 
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Table 1.  
Relative cell proliferation of cell lines 96 hours after reverse transfection with 
siRNAs . Cells were cultured in media with normal glucose concentration. 
 
 
  
  
N.T. si Cont si KIF11 si ME1-1 si ME1-2
HCC1187 107 100 18 51* 61*
MCF7 90 100 33 84# 84#
DU145 99 100 11 75* 48*
PC3 105 100 16 44* 24*
22RV-1 96 100 30 87# 93
HCT116 116 100 11 87# 19*
SW48 125 100 19 85* 86#
AsPC1 108 100 13 91* 48*
BxPC-3 113 100 24 83* 67*
DAN-G 135 100 14 58* 44*
HUP-T3 106 100 55 85# 64*
HUP-T4 100 100 36 68* 84*
*: p<0.01, #: p<0.05
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General Discussion 
 
In this study, I clarified the resistance mechanism of cancer cells against 
two cancer-related genes, aurora kinase B and malic enzyme 1. For Aurora 
kinase B inhibition, inherent gene expression of an anti-apoptotic gene, Bcl-
xL, is important for the resistance against BAX-induced apoptosis in 
polyploid cells. In the case of malic enzyme 1, alternation of dependency on a 
complementary metabolic pathway, glycolysis, to produce NADPH and to 
maintain redox homeostasis in cancer cells is key for acquired resistance 
against malic enzyme 1 inhibition. These results suggest that cancer cells 
utilize various biological mechanisms to adapt to stress of perturbations in 
their environments and to be resistant against suppression of cancer-related 
genes. Such flexibilities of cancer cells against stress increase the rate of 
recurrence of tumours after treatment and makes cancer treatment more 
difficult. I also demonstrated that survival and growth of cancer cells mainly 
depends on the resistance mechanism, when the cancer-related genes are 
suppressed; therefore, the resistance mechanism makes the cancer cells 
vulnerable. Furthermore, I demonstrated that simultaneous inhibition of a 
cancer-related gene and a key protein or pathway of a resistance could 
overcome resistance of cancer cells to treatment and inhibit cancer cells 
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effectively. These findings can help develop a new approach to treat cancers, 
especially those cancers which could be resistant to the initial treatment. 
Further, the results of this research could lead to the development of a 
combination strategy for cancer treatment based on synthetic lethality.  
Here, I demonstrated that the resistance mechanism against a certain 
treatment would be a vulnerability of cancer cells, which suggests a new 
strategy of combination therapy. Further investigations are needed to apply 
this approach to the clinical treatment. My demonstration in this study is 
limited to cancer cells, not in normal cells and tissues. To include the case of 
clinical treatment in which patients are treated with drugs mainly by systemic 
exposure into account I need to examine influences of combination treatment 
of drugs on normal cells and tissues including whether the combination 
treatment induces severe damage to them. To decrease toxicity of the 
combination therapy, selection of drugs, cancer types or dosing route should 
be investigated in pre-clinical study to ensure the margin between efficacy and 
toxicity. Also, patient or tumour selection markers should be prepared to 
select sensitive tumour populations to the treatment in clinic. In addition, the 
therapeutic effect of synthetic lethal combinations could be observed in 
homogeneous tumour but not clear in heterogeneous tumour. We need to 
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understand heterogeneity of tumour before treatment to maximize the effect of 
treatment. Additional investigation, understanding of tumours and 
development of therapeutic approach are required for satisfying unmet 
medical needs of cancer therapy. 
As described above, although there are some issues to be examined, the 
concept and approach demonstrated in this study are useful to treat cancer 
more effectively, and could result in the development of new drugs. The 
effective use of existing drug and the development of combination strategies 
involving  the aurora B kinase inhibitor and malic enzyme 1 inhibitor could 
contribute to cancer therapy.  
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